Androgen Deprivation Therapy and Newly Developed Neovascular Age-Related Macular Degeneration Risk in Patients with Prostate Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 May 25

PMID 38792519

Authors

Jee Soo Ha

Do Kyung Kim

Hye Sun Lee

Soyoung Jeon

Jinhyung Jeon

Daeho Kim

June Seok Kim

Byeongseon Kim

Min Kim

Kang Su Cho

Affiliations

Soon will be listed here.

Abstract

: to evaluate the association between androgen deprivation therapy (ADT) and newly developed neovascular age-related macular degeneration (AMD) in patients with prostate cancer. : We identified 228,803 men from the nationwide claims database in the Republic of Korea diagnosed with prostate cancer between 1 August 2009 and 31 December 2018 and followed until April 2021. Cases were defined as those newly diagnosed with neovascular AMD during follow-up. Cases were matched with controls based on age, index date, and follow-up duration, at a case-to-control ratio of 1:4. Adjusted odds ratios (aORs) of incident neovascular AMD associated with ADT were estimated using conditional logistic regression. : The main analysis included 1700 cases and 6800 controls, with a median follow-up of 3.42 years. ADT was associated with a reduced risk of incident neovascular AMD in patients with prostate cancer (aOR = 0.840; 95% confidence interval [CI], 0.743-0.951; = 0.0058) in the multivariable analysis. A cumulative ADT duration less than 1 year was associated with a reduced risk of neovascular AMD (aOR = 0.727; 95% CI, 0.610-0.866; = 0.0004); however, no association was observed when the duration of ADT was between 1 and 2 years (aOR = 0.862; 95% CI, 0.693-1.074; = 0.1854) or more than 2 years (aOR = 1.009; 95% CI, 0.830-1.226; = 0.9304). : In patients with prostate cancer, medical castration for less than a year is associated with a reduced risk of incident neovascular AMD. These results suggest that androgens are involved in the pathogenesis of neovascular AMD.

References

Park S, Lee J, Woo S, Ahn J, Shin J, Song S . Age-related macular degeneration: prevalence and risk factors from Korean National Health and Nutrition Examination Survey, 2008 through 2011. Ophthalmology. 2014; 121(9):1756-65. DOI: 10.1016/j.ophtha.2014.03.022. View

Michaud J, Billups K, Partin A . Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015; 7(6):378-87. PMC: 4647137. DOI: 10.1177/1756287215597633. View

Klein R, Klein B, Knudtson M, Wong T, Cotch M, Liu K . Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006; 113(3):373-80. DOI: 10.1016/j.ophtha.2005.12.013. View

Price D . Efficacy of androgen deprivation therapy and the role of oxidative stress. Ann Oncol. 2017; 28(3):451-453. PMC: 5834065. DOI: 10.1093/annonc/mdx001. View

Ahmad I, Sansom O, Leung H . Advances in mouse models of prostate cancer. Expert Rev Mol Med. 2008; 10:e16. DOI: 10.1017/S1462399408000689. View

Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G . Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate. 2000; 45(3):216-24. DOI: 10.1002/1097-0045(20001101)45:3<216::aid-pros3>3.0.co;2-c. View

Duncan K, Bailey K, Baxter J, Schwartz D . The human fetal retinal pigment epithelium: A target tissue for thyroid hormones. Ophthalmic Res. 1999; 31(6):399-406. DOI: 10.1159/000055564. View

Nguyen P, Alibhai S, Basaria S, DAmico A, Kantoff P, Keating N . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2014; 67(5):825-36. DOI: 10.1016/j.eururo.2014.07.010. View

Eisermann K, Broderick C, Bazarov A, Moazam M, Fraizer G . Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer. 2013; 12:7. PMC: 3616929. DOI: 10.1186/1476-4598-12-7. View

10.

Gopinath B, Liew G, Kifley A, Mitchell P . Thyroid Dysfunction and Ten-Year Incidence of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2016; 57(13):5273-5277. DOI: 10.1167/iovs.16-19735. View

11.

Doll J, Reiher F, Crawford S, Pins M, Campbell S, Bouck N . Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate. 2001; 49(4):293-305. DOI: 10.1002/pros.10025. View

12.

Schroder F, Tombal B, Miller K, Boccon-Gibod L, Shore N, Crawford E . Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2009; 106(2):182-7. DOI: 10.1111/j.1464-410X.2009.08981.x. View

13.

Chaker L, Buitendijk G, Dehghan A, Medici M, Hofman A, Vingerling J . Thyroid function and age-related macular degeneration: a prospective population-based cohort study--the Rotterdam Study. BMC Med. 2015; 13:94. PMC: 4407352. DOI: 10.1186/s12916-015-0329-0. View

14.

Stewart R, Panigrahy D, Flynn E, Folkman J . Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001; 165(2):688-93. DOI: 10.1097/00005392-200102000-00095. View

15.

Klaver C, Assink J, van Leeuwen R, Wolfs R, Vingerling J, Stijnen T . Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001; 42(10):2237-41. View

16.

Wang J, Rochtchina E, Lee A, Chia E, Smith W, Cumming R . Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. Ophthalmology. 2007; 114(1):92-8. DOI: 10.1016/j.ophtha.2006.07.017. View

17.

Mitchell P, Smith W, Attebo K, Wang J . Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995; 102(10):1450-60. DOI: 10.1016/s0161-6420(95)30846-9. View

18.

Ahn H, Lee H, Park J, Kim D, Kim M, Hwang H . Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study. Prostate Int. 2022; 9(4):197-202. PMC: 8740392. DOI: 10.1016/j.prnil.2021.05.001. View

19.

Kim J, Yoon S, Kim L, Kim D . Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. J Korean Med Sci. 2017; 32(5):718-728. PMC: 5383602. DOI: 10.3346/jkms.2017.32.5.718. View

20.

Pierorazio P, Ferrucci L, Kettermann A, Longo D, Metter E, Carter H . Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2009; 105(6):824-9. PMC: 2848292. DOI: 10.1111/j.1464-410X.2009.08853.x. View